Anna Couvillon

688 total citations
29 papers, 206 citations indexed

About

Anna Couvillon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anna Couvillon has authored 29 papers receiving a total of 206 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anna Couvillon's work include Prostate Cancer Treatment and Research (28 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Anna Couvillon is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Anna Couvillon collaborates with scholars based in United States, Germany and New Zealand. Anna Couvillon's co-authors include Ravi A. Madan, James L. Gulley, Barış Türkbey, William L. Dahut, Fatima Karzai, Peter A. Pinto, Eric A. Singer, Amy Hankin, Lisa M. Cordes and Howard L. Parnes and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

Anna Couvillon

28 papers receiving 204 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Couvillon United States	7	141	111	50	49	38	29	206
Sofia Westbom-Fremer Sweden	7	99 0.7×	187 1.7×	39 0.8×	68 1.4×	56 1.5×	12	299
Miao Huang China	9	159 1.1×	184 1.7×	33 0.7×	50 1.0×	61 1.6×	17	298
Godehard Lahmer Germany	8	61 0.4×	113 1.0×	44 0.9×	100 2.0×	19 0.5×	14	246
Anne Sibille Belgium	9	83 0.6×	137 1.2×	31 0.6×	28 0.6×	53 1.4×	21	204
Riccardo Galassi Italy	8	166 1.2×	101 0.9×	144 2.9×	92 1.9×	42 1.1×	15	327
Rana Harb United States	7	152 1.1×	116 1.0×	17 0.3×	63 1.3×	47 1.2×	9	211
Jian Zhong China	9	104 0.7×	114 1.0×	75 1.5×	52 1.1×	63 1.7×	23	256
Norimitsu Kasahara Japan	10	163 1.2×	196 1.8×	34 0.7×	26 0.5×	40 1.1×	29	301
Nicolas Signolle France	9	45 0.3×	136 1.2×	63 1.3×	42 0.9×	66 1.7×	17	239
Mélodie Tazdait France	4	138 1.0×	229 2.1×	64 1.3×	51 1.0×	15 0.4×	7	276

Countries citing papers authored by Anna Couvillon

Since Specialization

Citations

This map shows the geographic impact of Anna Couvillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Couvillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Couvillon more than expected).

Fields of papers citing papers by Anna Couvillon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Couvillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Couvillon. The network helps show where Anna Couvillon may publish in the future.

Co-authorship network of co-authors of Anna Couvillon

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Couvillon. A scholar is included among the top collaborators of Anna Couvillon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Couvillon. Anna Couvillon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Couvillon, Anna, Barış Türkbey, Peter L. Choyke, et al.. (2023). Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).. Journal of Clinical Oncology. 41(6_suppl). 390–390. 1 indexed citations

Madan, Ravi A., Renee N. Donahue, Fatima Karzai, et al.. (2022). 1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1191–S1191. 1 indexed citations

Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2022). PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 40(16_suppl). e17046–e17046. 1 indexed citations

Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2021). Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 39(15_suppl). e17044–e17044. 1 indexed citations

Madan, Ravi A., Susan F. Slovin, Lauren C. Harshman, et al.. (2020). 681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc). Annals of Oncology. 31. S542–S542. 1 indexed citations

Gandhy, Shruti U., Fatima Karzai, Jennifer L. Marté, et al.. (2020). PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology. 38(6_suppl). 105–105. 6 indexed citations

Madan, Ravi A., Fatima Karzai, Daniel P. Petrylak, et al.. (2019). A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 173–173. 3 indexed citations

Dahut, William L., Anna Couvillon, Peter A. Pinto, Barış Türkbey, & Fatima Karzai. (2019). Natural history and imaging in men with high genetic risk for developing prostate cancer.. PubMed. 26(5 Suppl 2). 7–8. 3 indexed citations

Harmon, Stephanie A., Esther Mena, Joanna H. Shih, et al.. (2018). A Prospective Comparison of ¹⁸F-Sodium Fluoride PET/CT and PSMA-Targeted ¹⁸F-DCFBC PET/CT in Metastatic Prostate Cancer. Journal of Nuclear Medicine. 59(11). 1665–1671. 37 indexed citations

10.

Chen, Gang, Fatima Karzai, Ravi A. Madan, et al.. (2018). CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). TPS5096–TPS5096. 1 indexed citations

11.

Madan, Ravi A., Fatima Karzai, Marijo Bilušić, et al.. (2018). Immunotherapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 215–215. 5 indexed citations

12.

Singh, Harbhej, Fatima Karzai, Marc R. Theoret, et al.. (2018). Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. Annals of Oncology. 29. viii297–viii297. 1 indexed citations

13.

Madan, Ravi A., Barış Türkbey, Lauren M. Lepone, et al.. (2017). Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation.. Journal of Clinical Oncology. 35(6_suppl). 30–30. 4 indexed citations

14.

Karzai, Fatima, Ravi A. Madan, Helen Owens, et al.. (2017). Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5026–5026. 18 indexed citations

15.

Brown, Anna M., Sandeep Sankineni, Marcelino Bernardo, et al.. (2015). Ferumoxytol enhanced MRI for lymph node staging in prostate cancer.. Journal of Clinical Oncology. 33(7_suppl). 208–208. 2 indexed citations

16.

Couvillon, Anna, Barış Türkbey, Maria Liza Lindenberg, et al.. (2015). Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.. Journal of Clinical Oncology. 33(7_suppl). 122–122. 2 indexed citations

17.

Karzai, Fatima, Ravi A. Madan, Marc R. Theoret, et al.. (2015). Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(7_suppl). 235–235. 2 indexed citations

18.

Singh, Nishith K., Joseph W. Kim, Christopher R. Heery, et al.. (2013). A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer.. Journal of Clinical Oncology. 31(15_suppl). TPS5104–TPS5104. 2 indexed citations

19.

Singer, Eric A., Aradhana Kaushal, Barış Türkbey, et al.. (2012). Active surveillance for prostate cancer. Current Opinion in Oncology. 24(3). 243–250. 34 indexed citations

20.

Singh, Nishith K., Marijo Bilušić, Joseph W. Kim, et al.. (2012). Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.. Journal of Clinical Oncology. 30(15_suppl). TPS4701–TPS4701. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact